Effect of Platinum-Based Chemotherapy on PD-L1 Expression on Tumor Cells in Non-small Cell Lung Cancer
| Autor: | Jin Haeng Chung, Kyu Sang Lee, Jong Seok Lee, Jin Won Kim, Keun Wook Lee, Soo Mee Bang, Yu Jung Kim, Junghoon Shin, Ji Won Kim, Ji Yun Lee, Se Hyun Kim, Jee Hyun Kim, Jeong Ok Lee, Koung Jin Suh |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
Oncology PD-L1 Adult Male Cancer Research medicine.medical_specialty Lung Neoplasms medicine.medical_treatment B7-H1 Antigen Non-small cell lung carcinoma 03 medical and health sciences symbols.namesake 0302 clinical medicine McNemar's test Internal medicine Carcinoma Non-Small-Cell Lung medicine Humans Lung cancer Neoadjuvant therapy Fisher's exact test Platinum Aged Retrospective Studies Chemotherapy biology business.industry Middle Aged medicine.disease Prognosis Survival Analysis Neoadjuvant Therapy Up-Regulation Gene Expression Regulation Neoplastic 030104 developmental biology Treatment Outcome Chemotherapy Adjuvant 030220 oncology & carcinogenesis biology.protein symbols Immunohistochemistry Original Article Female Non small cell business |
| Zdroj: | Cancer Research and Treatment : Official Journal of Korean Cancer Association |
| ISSN: | 2005-9256 1598-2998 |
| Popis: | PURPOSE Programmed death-1 (PD-1)/PD-1 ligand (PD-L1) axis blockades have revolutionized the treatment of advanced non-small cell lung cancer (NSCLC). We assessed the effect of platinum-based chemotherapy on tumor PD-L1 expression and its clinical implications. MATERIALS AND METHODS We used immunohistochemistry to retrospectively evaluate the percentage of tumor cells with membranous PD-L1 staining (tumor proportion score) in paired tumor specimens obtained before and after platinum-based neoadjuvant chemotherapy (NACT) in 86 patients with NSCLC. We analyzed the correlation between the change in PD-L1 tumor proportion score and clinicopathologic characteristics, response to NACT, and survival. RESULTS The PD-L1 tumor proportion score increased in a significant proportion of patients with NSCLC after platinum-based NACT (Wilcoxon signed-rank test, p=0.002). That pattern was consistent across clinically defined subgroups except for patients with partial response to NACT. Tumors from 26 patients (30.2%) were PD-L1‒negative before NACT but PD-L1-positive after NACT, whereas the reverse pattern occurred in six patients (7%) (McNemar's test, p < 0.001). Increase in PD-L1 tumor proportion score was significantly associated with lack of response to NACT (Fisher exact test, p=0.015). There was a tendency, albeit not statistically significant, for patients with an increase in PD-L1 tumor proportion score to have shorter survival. CONCLUSION Tumor PD-L1 expression increased after platinum-based NACT in a significant proportion of patients with NSCLC. Increase in tumor PD-L1 expression may predict poor clinical outcome. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|